Marché mondial des dispositifs d’assistance ventriculaire de troisième génération – Tendances et prévisions du secteur jusqu’en 2030

 Analyse et taille du marché des dispositifs d'assistance ventriculaire de troisième génération

Selon l'Organisation mondiale de la santé (OMS), 17,9 millions de personnes meurent chaque année des suites de maladies cardiovasculaires dans le monde. Cela représente 35 % de tous les décès dans le monde. De plus, les crises cardiaques et les accidents vasculaires cérébraux (AVC) sont responsables de 85 % de tous les décès dus à des maladies cardiovasculaires. Selon un article de juillet 2020 publié dans le Cureus Journal of Medical Science, les cardiopathies ischémiques (CCI) sont l'une des principales causes de décès dans le monde. Les cardiopathies ischémiques touchent environ 126 millions de personnes (1 655 pour 100 000), soit environ 1,72 % de la population mondiale. D'ici 2030, la prévalence mondiale des cardiopathies ischémiques devrait dépasser 1 845 pour 100 000 personnes.

Français Data Bridge Market Research analyse que le marché des dispositifs d'assistance ventriculaire de troisième génération, qui était de 2,5 milliards USD en 2022, devrait atteindre 9,08 milliards USD d'ici 2030, à un TCAC de 17,50 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des dispositifs d'assistance ventriculaire de troisième génération      

Market Definition

Third-generation ventricular assist devices (VADs) are continuous-flow rotary pumps with a fully levitated impeller/rotor and no mechanical contact between the rotating and stationary parts of the pump in normal operation. Third-generation VADs have emerged with the promise of improved hemocompatibility and durability over second-generation devices. However, most third-generation devices have not demonstrated a significant advantage over their second-generation counterparts, frequently trading an improvement in one aspect of performance for a disadvantage in another.

Global Third Generation Ventricular Assist Devices Market Dynamics

Drivers

• Technological advancements

The VAD market is constantly changing, with key players investing in product innovation and development. The market for VAD is expected to be driven by technological advancements combined with timely regulatory approvals in the form of small-size devices with features such as infection control. Berlin Heart announced in June 2020 that the US FDA's required Post Market Approval (PMA) for EXCOR Pediatric VAD was completed. Furthermore, benefits associated with the use of VADs include increased abidance, functionality, and durability, which increase product adoption and thus support market growth.

• Rising private equity firms

Private equity firms and venture capitalists are making investments in the growing third generation VAD market to promote product development. For instance, CorWave raised USD 40.0 million in a Series C funding round led by three new and returning investors in January 2021 for its implantable heart pump based on a novel technology, the wave membrane pump, including Novo Holdings, Bpifrance, Sofinnova Partners, Seventure, Ysios Capital, European Commission, Singaporean family office M&L Healthcare, and Financière Arbevel.

Opportunities

• Novel advancements

Advances in novel VADs for surgical interventions, particularly in paediatric patients suffering from cardiac disorders, are expected to increase the demand. For instance, the US Food and Drug Administration graded the continuous-flow LVADs, Micromed HeartAssist 5TM Pediatric VAD, and Berlin HeartTM EXCOR paediatric VAD for paediatric patients. Since 2011, Berlin HeartTM EXCOR has been approved for use as a bridge-to-transplantation device.

•Increasing incidence of organ transplantation

The rising prevalence of cardiovascular diseases and growing risks of organ failures is supporting the growth in organ transplant demand. The shortage of organ donors delays the organ transplantation procedure. As per United Network for Organ Sharing, nearly 121,016 people need organ transplantation and approximately 77,725 people are on the active waiting list.

Restraints/Challenges

• High costs

High costs associated with procedure and device usage, a lack of government reimbursement policies, and an increasing number of serious risks involved in procedure are acting as market restraints for the growth of third-generation ventricular assist devices during the forecast period. The most difficult challenge for market growth will be the increased development of affordable, small, and efficient devices.

This third generation ventricular assist devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the third generation ventricular assist devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Third Generation Ventricular Assist Devices Market

The ongoing Covid-19 pandemic has had a negative impact on the third generation ventricular assist devices market, with the government imposing temporary lockdowns and travel restrictions, resulting in a decrease in the number of surgical procedures. For instance, the global revenue of the ABIOMED Impella heart pump was impacted in the fourth quarter of FY2020 due to lower patient utilization and the significant impact of the COVID-19 pandemic on surgeries, elective medical procedures, and fewer patients seeking treatment at hospitals.

Recent Developments

• In June 2020, The FDA approved the company's First-in-Human Trial of Impella ECP, which will be studied in high-risk percutaneous coronary intervention patients. In addition, to strengthen their business and expand the reach of their device, they are implementing various strategies such as mergers and acquisitions and expanding their manufacturing facilities.

Global Third Generation Ventricular Assist Devices Market Scope

The third generation ventricular assist devices market is segmented on the basis of product, application, age, flow, design, and technology. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Left Ventricular Assist Devices (LVADs)
• Right Ventricular Assist Devices (RVADs)
• Biventricular Assist Devices (BIVADs)
• Percutaneous Ventricular Assist Devices (PVADs)
• Total Artificial Heart (TAH)

 Application

• Destination Therapy
• Bridge-to-Candidacy (BTC) Therapy
• Bridge-to-Transplant (BTT) Therapy
• Bridge-to-Recovery (BTR) Therapy
• Others

 Age

• Below 18 Years
• 19-39 Years
• 40-59 Years
• 60-79 Years
• Above 80 Years

 Flow

• Pulsatile Flow
• Continuous Flow
• Axial continuous flow
• Centrifugal continuous flow

 Design

• Transcutaneous
• Implantable

 Technology

• Magnetic
• Hydrodynamic Levitation

Third Generation Ventricular Assist Devices Market Regional Analysis/Insights

The third generation ventricular assist devices market is analyzed and market size insights and trends are provided by country, product, application, age, flow, design, and technology as referenced above.

The countries covered in the third generation ventricular assist devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the third generation ventricular assist devices market because of rising public health awareness, the prevalence of well-established healthcare policies, and the region's high prevalence of cardiovascular disorders.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the growing number of initiatives such as “Make in India” along with surging levels of investment for the growth of the healthcare sector in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The third generation ventricular assist devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for third generation ventricular assist devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the third generation ventricular assist devices market. The data is available for historic period 2011-20201.

Competitive Landscape and Third Generation Ventricular Assist Devices Market Share Analysis

The third generation ventricular assist devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to third generation ventricular assist devices market.

Some of the major players operating in the third generation ventricular assist devices market are:

• ABIOMED (U.S.)
• Asahi Kasei Corporation (Japan)
• Abbott (U.S.)
• Calon Cardio (U.K.)
• Jarvik Heart, Inc. (U.S.)
• Medtronic (Ireland)
• Terumo Corporation (Japan)
• BiVACOR Inc. (U.S.)
• Cardiobridge GmbH (Germany)
• CHF Solutions, Inc. (U.S.)
• Evaheart, Inc. (U.S.)
• LivaNova PLC (U.K.)
• CorWave SA (France)
• Fresenius Medical Care AG & Co. KGaA (Germany)
• MiTiHeart Corporation (U.S.)
• Getinge AB (Sweden)
• SynCardia Systems, LLC (U.S.)
• Teleflex Incorporated (U.S.)
• Fondation Mayo pour l'éducation et la recherche médicales (MFMER) (États-Unis)

Méthodologie de recherche : Marché mondial des dispositifs d'assistance ventriculaire de troisième génération

La collecte des données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. L'analyse des parts de marché et l'analyse des tendances clés sont également les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et la part des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande de renseignements pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader dans la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'aux stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez pour obtenir des données dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Factbook) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport. 

SKU-56781